Wolverine

Wolverine is a formulated dual blend of BPC-157 and TB-500. It is not a novel chemical entity and it does not have a CAS number as a whole.

Laboratories that need unambiguous single-substance certificates should order BPC-157 or consult TB-500 research documentation separately. Blends suit work where the combination itself is the documentation object.

KLOW is a different blend that also contains BPC-157 and TB-500 plus GHK-Cu and KPV — never share lots or certificates across these SKUs.

BPC-157 literature is dominated by preclinical injury-model work; TB-500 / thymosin β4 fragment literature emphasises actin binding and cell-migration models. Neither body of work was generated using this specific combination.

Anti-doping status of the named components applies to the blend: both BPC-157 and TB-500 warrant compliance awareness in sport-connected laboratories.

Meaningful blend analytics ask whether both components are present and identifiable. A single purity percentage is not sufficient characterisation.

Store sealed at 2–8 °C. Wolverine is not an approved medicine and is not for human use.

Supplied strictly for in vitro laboratory research. The catalog presentation is a 10 mg lyophilised blend vial with lot-linked documentation when published.

Two-component repair-pathway blends are common in research supply, but they are easy to mis-file next to single-sequence BPC-157 stock. Warehouse and LIMS naming should make the blend status obvious at a glance.

Because BPC-157 and TB-500 both appear on anti-doping prohibited lists, laboratories connected to athlete populations or testing programmes should treat Wolverine as carrying those same compliance constraints even though it is supplied only for in vitro research.

Certificate review for Wolverine should confirm both components where analytical methods resolve them. If your SOP requires a single-substance COA for either component, purchase that component as its own SKU instead of relying on the blend presentation.

This monograph is a reference article for laboratory purchasers and documentation staff. It summarises chemical identity, literature context and handling constraints that affect analytical work. It is not a protocol, not a dosing guide and not a substitute for institutional SOP review.

Where pharmaceutical or clinical papers are cited, they are included only to anchor compound identity and regulatory status. They do not authorise human use of VaultLabs research material, and they do not convert a lyophilised reference vial into a finished medicine.

If a certificate, label and monograph appear to disagree, stop and query support with the lot number before the material enters an experiment. Lot-linked certificates override general catalog copy for the specific unit in hand.

VaultLabs updates monographs when catalog strengths or documentation practice change. The updatedAt field marks the editorial revision date for this article, not the manufacture date of any particular lot.

All VaultLabs materials named here remain research-use-only: not for human consumption, not for medical use, and not for personal application under any reading of the surrounding literature.

Dual-component repair-pathway documentation

Blend vs single-SKU analytical comparisons

Component identity and ratio verification

2–8 °C (lyophilized, sealed)

2–8 °C sealed; follow product page and batch COA notes.

Multi-component lyophilized blends require component-level handling awareness — do not assume single-peptide SOPs transfer unchanged.